ES2182133T3 - Composiciones farmaceuticas para liofilizar. - Google Patents

Composiciones farmaceuticas para liofilizar.

Info

Publication number
ES2182133T3
ES2182133T3 ES97950542T ES97950542T ES2182133T3 ES 2182133 T3 ES2182133 T3 ES 2182133T3 ES 97950542 T ES97950542 T ES 97950542T ES 97950542 T ES97950542 T ES 97950542T ES 2182133 T3 ES2182133 T3 ES 2182133T3
Authority
ES
Spain
Prior art keywords
liofilize
pharmaceutical compositions
polyol
mannitol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97950542T
Other languages
English (en)
Inventor
Chris Bland
Gerald Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Application granted granted Critical
Publication of ES2182133T3 publication Critical patent/ES2182133T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición farmacéutica que comprende un compuesto análogo a nucleótido, manitol y un aditivo de modificación que es cloruro de sodio o un poliol.
ES97950542T 1996-12-20 1997-12-11 Composiciones farmaceuticas para liofilizar. Expired - Lifetime ES2182133T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2182133T3 true ES2182133T3 (es) 2003-03-01

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97950542T Expired - Lifetime ES2182133T3 (es) 1996-12-20 1997-12-11 Composiciones farmaceuticas para liofilizar.

Country Status (35)

Country Link
US (1) US6114313A (es)
EP (1) EP1007094B1 (es)
JP (1) JP4488538B2 (es)
KR (1) KR100552880B1 (es)
CN (1) CN1121875C (es)
AR (1) AR010377A1 (es)
AT (1) ATE221787T1 (es)
AU (1) AU758857B2 (es)
BR (1) BR9713974B1 (es)
CA (1) CA2275153C (es)
CZ (1) CZ300635B6 (es)
DE (1) DE69714616T2 (es)
DK (1) DK1007094T3 (es)
EE (1) EE03857B1 (es)
ES (1) ES2182133T3 (es)
FR (1) FR15C0060I2 (es)
HU (1) HU226616B1 (es)
ID (1) ID21635A (es)
IL (1) IL130449A0 (es)
IS (1) IS1897B (es)
MY (1) MY121982A (es)
NO (1) NO327142B1 (es)
NZ (1) NZ336027A (es)
PL (1) PL190493B1 (es)
PT (1) PT1007094E (es)
RU (1) RU2205012C2 (es)
SA (1) SA97180719B1 (es)
SE (1) SE9604795D0 (es)
SI (1) SI1007094T1 (es)
SK (1) SK283137B6 (es)
TR (1) TR199901412T2 (es)
TW (1) TW522015B (es)
UA (1) UA66779C2 (es)
WO (1) WO1998028009A1 (es)
ZA (1) ZA9711055B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) * 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (es) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Ａｔｐ凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge

Also Published As

Publication number Publication date
NO993067D0 (no) 1999-06-21
RU2205012C2 (ru) 2003-05-27
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
DK1007094T3 (da) 2002-10-28
CA2275153C (en) 2008-03-25
AR010377A1 (es) 2000-06-07
IS1897B (is) 2003-10-20
EP1007094A1 (en) 2000-06-14
HK1026366A1 (en) 2000-12-15
IL130449A0 (en) 2000-06-01
MY121982A (en) 2006-03-31
NZ336027A (en) 2001-03-30
DE69714616D1 (de) 2002-09-12
EP1007094B1 (en) 2002-08-07
WO1998028009A1 (en) 1998-07-02
US6114313A (en) 2000-09-05
ZA9711055B (en) 1998-07-08
CN1240362A (zh) 2000-01-05
CZ300635B6 (cs) 2009-07-08
FR15C0060I2 (fr) 2016-04-22
HUP0000572A3 (en) 2002-10-28
PT1007094E (pt) 2002-12-31
FR15C0060I1 (es) 2015-10-23
EE9900260A (et) 2000-02-15
UA66779C2 (uk) 2004-06-15
PL334006A1 (en) 2000-01-31
PL190493B1 (pl) 2005-12-30
TR199901412T2 (xx) 1999-08-23
CN1121875C (zh) 2003-09-24
BR9713974A (pt) 2000-04-11
SK283137B6 (sk) 2003-03-04
ATE221787T1 (de) 2002-08-15
KR20000069598A (ko) 2000-11-25
HUP0000572A2 (hu) 2001-05-28
SE9604795D0 (sv) 1996-12-20
SI1007094T1 (en) 2003-02-28
SA97180719B1 (ar) 2006-05-13
EE03857B1 (et) 2002-10-15
BR9713974B1 (pt) 2010-02-23
AU758857B2 (en) 2003-04-03
TW522015B (en) 2003-03-01
NO327142B1 (no) 2009-05-04
JP2001507022A (ja) 2001-05-29
ID21635A (id) 1999-07-08
DE69714616T2 (de) 2003-04-03
CZ220199A3 (cs) 1999-11-17
CA2275153A1 (en) 1998-07-02
JP4488538B2 (ja) 2010-06-23
NO993067L (no) 1999-08-09
IS5064A (is) 1999-06-03
AU5351598A (en) 1998-07-17
HU226616B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
ES2189256T3 (es) Composiciones de mezclas de ester de cianoacrilato.
ES2145115T3 (es) Composiciones inyectables a base de derivados de taxanos.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
MX173582B (es) Espesante de arcilla para emplear en sistemas basados en agua y compuestos de union que contienen esas composiciones
DK0876140T3 (da) Forbedrede kontrastmiddelopløsninger til intravasal anvendelse
DE69622825D1 (de) Schmierfettzusammensetzung mit verbesserten Verschleissschutzeigenschaften
ATE226240T1 (de) Xanthangummi enthaltende saure reinigungsmittel
PL345550A1 (en) Pharmaceutical compositions comprising 2-quinolones
FI935847L (fi) L-DOPA-esterikoostumukset
FI955851L (fi) Synergistisesti stabiloituja nestemäisiä entsymaattisia koostumuksia
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ES2188763T3 (es) Factor del tipo relaxina y metodos y usos del mismo.
DK0460062T3 (da) Huperzin A-analoger
DE69418500D1 (de) Feste Schmiermittelzusammensetzung
AR015945A1 (es) Composiciones de spray para el cabello autofobicas
ID16361A (id) Komposisi kalsium karbonat yang tahan terhadap asam dan penggunaannya
MY121982A (en) Pharmaceutical compositions for freeze drying
DE69428788D1 (de) Parfumzusammensetzung
ID17875A (id) Komposisi farmasi yang mengandung asam 4-oksobutanoat
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
CO4930269A1 (es) Composiciones farmaceuticas
DK0977871T3 (da) Neurotrypsin
BG100248A (bg) Инхибитори на скваленсинтетаза
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.